Cytox is commercialising an in vitro genetic test for the diagnosis of early stage Alzheimer’s Disease (AD) supported by leading academics from the Universities of Oxford, Birmingham, Cardiff and UCL.
Cytox has created a DNA-profiling array which is interpreted using a polygenic risk score (PRS) algorithm to determine the likelihood of developing AD. The development of new AD drugs suffers from a >99% failure rate. Due to the lack of an effective early diagnostic test, costly PET scans are used to identify AD patients, resulting in extremely high clinical trial recruitment costs. The availability of an accurate early stage diagnostic will help accelerate AD drug development.